Completed Studies

UNIVERSITY OF MIAMI STUDY

The University of Miami tested the ability of BioLexa’s DTPA chelator to synergize with the antibiotic in an animal study. Specifically, the pre-clinical study introduced high levels of Staph bacteria to wounds on the skin of pigs, as pig skin is the closet animal model to human skin. The results, as set forth in this chart, show significant reduction in bacterial infection. In some cases, the bacterial count was below detectable levels.

Link to Study: https://hoththerapeutics.com/wp-content/uploads/2018/01/Miami-Study.pdf

MASSACHUSETTS GENERAL HOSPITAL – DIABETIC FOOT ULCER PILOT STUDY

This pilot study was designed to establish foundational protocols for assessing effectiveness of a therapeutic compound developed by Hoth Therapeutics, the BioLexa Platform, for accelerating and improving wound healing in the context of acute and chronic diabetic ulcers, using an animal model of impaired wound healing developed at Massachusetts General Hospital (MGH).

Link to Results: https://www.prnewswire.com/news-releases/hoth-therapeutics-inc-announces-positive-results-from-pilot-study-of-biolexa-on-diabetic-skin-ulcers-300888346.html

MINIPIG PHASE I IN-LIFE DOSE ESCALTION STUDY 

MINIPIG GLP 28-DAY REPEAT DOSE TOXICITY 

BOVINE CORNEAL OPACITY AND PERMEABILITY TEST 

BEUHLER SENSITIZATION STUDY

 

PROPOSED FUTURE STUDIES:

FRANZ CELL ASSAY – IN VITRO PERCUTANEOUS ABSORPTION STUDY

CLINICAL TRIAL IN HUMANS

INVESTOR RELATIONS

Hoth Therapeutics seeks to enhance shareholder value not only through business performance and practices, but also through responsible and effective communication with its shareholders.